Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer

Supportive Care in Cancer

Volumn 15, Issue 11, 2007, Pages 1293-1300

  Einhorn, Lawrence H ^a,b   Brames, Mary J ^a   Dreicer, Robert ^c   Nichols, Craig R ^d   Cullen Jr , Michael T ^e   Bubalo, Joseph ^d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Lance Armstrong Foundation   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e GUILFORD PHARMACEUTICALS INC   (United States)

Author keywords

Chemotherapy induced nausea and vomiting; Cisplatin; Multiple day; Palonosetron; Testicular cancer

Indexed keywords

BLEOMYCIN; CISPLATIN; DEXAMETHASONE; ETOPOSIDE; IFOSFAMIDE; PALONOSETRON;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CARDIOVASCULAR EFFECT; CHEMOTHERAPY INDUCED EMESIS; CHRONOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; FUNCTIONAL ASSESSMENT; GERM CELL TUMOR; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT;

ADULT; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CISPLATIN; DEXAMETHASONE; DRUG THERAPY, COMBINATION; DRUG TOXICITY; HUMANS; ISOQUINOLINES; MALE; NAUSEA; NEOPLASMS, GERM CELL AND EMBRYONAL; QUINUCLIDINES; UNITED STATES; VOMITING;

EID: 35348818158     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-007-0255-6     Document Type: Article

References (25)

1. Aapro M, Grunberg S, Manikhas G, Olivares G, Suarez T, Tjulandin S, Bertoli L, Yunus F, Morrica B, Lordick F, Macciocchi A (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441-1449
2. Baltzer L, Pisters KMW, Kris MG et al (1993) High-dose ondansetron plus dexamethasone for the prevention of nausea and vomiting with multiple-day cisplatin chemotherapy [abstract]. J Clin Oncol 12:462 (Abstract 1607)
3. Cartmell A, Ferguson S, Yanagihara R et al (2003) Protection against chemotherapy-induced nausea and vomiting (CINV) is maintained over multiple cycles of moderately or highly emetogenic chemotherapy by palonosetron (PALO), a potent 5-HT3 receptor antagonist (RA) [abstract and poster]. Proc Am Soc Clin Oncol 22:756 (Abstract 3041)
4. De Mulder PH, Seynaeve C, Vermorken JB, van Liessum PA, Mols-Jevdevic S, Allman EL, Beranek P, Verweij J (1990) Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. Ann Intern Med 113:834-840
5. De Mulder PHM, Roila F, Kris MG, Marty MM (1998) Consensus regarding multiple day and rescue antiemetic therapy. Support Care Cancer 6:248-252
6. Einhorn LH, Nagy C, Werner K, Finn AL (1990) Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy. J Clin Oncol 8:731-735
7. Einhorn LH, Rapoport B, Koeller J, Grunberg SM, Feyer P, Rittenberg C, Aapro M (2005) Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 13:112-116
8. 3 receptor antagonist. Results of a phase III, single-dose trial versus dolasetron. Cancer 98:2473-2482
9. Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A (2004) Efficacy, safety, and pharmacokinetics of palonosetron in patients receiving highly emetogenic, cisplatin-based chemotherapy: a dose-ranging, clinical study. Ann Oncol 15:330-337
10. Ettinger DS, Bierman PJ, Bradbury B et al for the National Comprehensive Cancer Network (2004) Clinical practice guidelines in oncology: antiemesis. J Natl Compr Canc Netw 2:470-490
11. Fox SM, Einhorn LH, Cox E, Powell N, Abdy A (1993) Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy. J Clin Oncol 11:2391-2395
12. Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570-1577
13. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Groshen S, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister DG (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 17:2971-2994
14. Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, Tattersall MH (1996) On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7:189-195
15. Hainsworth J, Harvey W, Pendergrass K, Kasimis B, Oblon D, Monaghan G, Gandara D, Hesketh P, Khojasteh A, Harker G, York M, Siddiqui T, Finn A (1991) A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol 9:721-728
16. 3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 18:163-173
17. Hesketh PJ, Harvey WH, Harker WG, Beck TM, Ryan T, Bricker LJ, Kish JA, Murphy WK, Hainsworth JD, Haley B, Plagge P, Flack NE (1994) A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 12:596-600
18. Hunt TL, Gallagher SC, Cullen MT Jr, Shah AK (2005) Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects. J Clin Pharmacol 45:589-596
19. 3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. Eur J Cancer 33:66-74
20. Martin CG, Rubenstein EB, Elting LS, Kim YJ, Osoba D (2003) Measuring chemotherapy-induced nausea and emesis. Cancer 98:645-655
21. 3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322:816-821
22. Osoba D, Zee B, Warr D, Kaizer L, Latreille J, Pater J (1996) Quality of life studies in chemotherapy-induced emesis. Oncology 53(Suppl):92-95
23. Roila F, Tonato M, Cognetti F, Cortesi E, Favalli G, Marangolo M, Amadori D, Bella MA, Gramazio V, Donati D, Ballatori E, Del Favero A (1991) Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 9:675-678
24. Stoltz R, Cyong JC, Shah A, Parisi S (2004) Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in US and Japanese healthy subjects. J Clin Pharmacol 44:520-531
25. Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94:1011-1015